IL6 and congenital rubella syndrome: While there was a rapid clinical improvement of CRS symptoms, it remains unclear if targeting IL-6 signaling interferes with the activity of blinatumomab or whether the two therapies can be delivered simultaneously without affecting the anti-leukemic effect.